Michael Solomon, MD
Pulmonary Disease · Chevy Chase, MDNPI 1205819026
Payments from drug & device makers
Across 256 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Insmed, Inc.$832
- Boehringer Ingelheim$445
- Actelion Pharmaceuticals US, Inc.$213
- Grifols USA, LLC$196
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,40998%
- Education$1162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 75 | $1,204 |
| AstraZeneca(2 entities) | 45 | $1,106 |
| Insmed, Inc. | 35 | $832 |
| Boehringer Ingelheim | 15 | $445 |
| Actelion Pharmaceuticals US, Inc. | 8 | $213 |
| Grifols USA, LLC | 10 | $196 |
| Bayer | 6 | $139 |
| Regeneron Healthcare Solutions, Inc. | 6 | $131 |
| Sanofi | 5 | $119 |
| United Therapeutics Corporation | 1 | $110 |
| Merck | 5 | $100 |
| Advanced Respiratory, Inc | 4 | $88 |
| Johnson & Johnson | 5 | $79 |
| Mylan Specialty L.p. | 4 | $75 |
| Electromed, Inc. | 4 | $66 |
| Astellas Pharma US Inc | 3 | $66 |
| Boston Scientific | 2 | $61 |
| Vapotherm Inc | 2 | $48 |
| Genentech USA, Inc. | 2 | $48 |
| Gilead | 2 | $44 |
| Pfizer | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Laborie Medical Technologies Corp. | 1 | $33 |
| Circassia Inc. | 2 | $30 |
| Monaghan Medical Corporation | 1 | $29 |
| Shire North American Group Inc | 2 | $27 |
| Amgen | 1 | $26 |
| Novartis | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Resmed Corp | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Pulmonx Corporation | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,526 in reported general payments places this provider in the 65th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $623,678 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $127,527 |
| Breo ElliptaFluticasone/Vilanterol | 130 | $90,395 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 85 | $72,036 |
| Dupixent SyringeDupilumab | 13 | $57,340 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $44,331 |
| Spiriva RespimatTiotropium Bromide | 50 | $43,514 |
| Arnuity ElliptaFluticasone Furoate | 98 | $41,092 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $27,010 |
| EliquisApixaban | 21 | $23,195 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 23 | $22,763 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $15,815 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $13,698 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $8,405 |
| Fluticasone Propionate HfaFluticasone Propionate | 16 | $6,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $445 | $711,522144 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,204 | $358,060447 claims |
| AstraZenecaBevespi Aerosphere, Symbicort | $1,106 | $38,57858 claims |
| PfizerEliquis | $42 | $23,19521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 297 pulmonary disease providers in Maryland.
Other pulmonary disease in Chevy Chase
- Carlos PiconeChevy Chase$89K
- Richard BernsteinAnnapolis$5.7M
- Alan SchwartzBaltimore$1.6M
- Sonye DanoffBaltimore$1.5M
- Michael DrummondBaltimore$1.4M
- da Wei LiaoBethesda$1.3M
- Paul HassounBaltimore$1.3M
- Lonny YarmusBaltimore$1.2M
- Jonathan SevranskyBaltimore$971K
- Robert ChasseSalisbury$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.